3-[(E)-2-1,3-dioxolan-2-yl-vinyl]quinoline | 1266112-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-[(E)-2-1,3-dioxolan-2-yl-vinyl]quinoline
• CAS: 1266112-83-7
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: FSLVUEAPUILPHH-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  3-[(E)-2-1,3-dioxolan-2-yl-vinyl]quinoline 在 盐酸 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 6.0h， 生成 3-[(E)-3-quinolin-3-yl-prop-2-en-(E)-ylidene]-1-(tetrahydropyran-2-yloxy)pyrrolidin-2-one
  参考文献：
  名称：

  5-Membered cyclic hydroxamic acids as HDAC inhibitors

  摘要：

  The new histone deacylases inhibitors (HDACi) were synthesized in the class of 5-membered cyclic hydroxamic acids (5-CHA), showing medium size CHA as a new Zn-binding group. New reaction sequence was proposed for the synthesis of 5-membered alkylidene-cyclic-hydroxamic acids starting from butyrolactone. Compound 10c showed low mu M activity on HeLa cell extracts. From these results, cyclic hydroxamic acids will be further investigated to find more potent compounds.

  DOI：

  10.3109/14756366.2014.912214
• 作为产物：
  描述：

  3-喹啉甲醛 、 三丁基（1,3-二恶烷-2-基甲基）溴化鏻 在 sodium ethanolate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以29%的产率得到3-[(E)-2-1,3-dioxolan-2-yl-vinyl]quinoline
  参考文献：
  名称：

  5-Membered cyclic hydroxamic acids as HDAC inhibitors

  摘要：

  The new histone deacylases inhibitors (HDACi) were synthesized in the class of 5-membered cyclic hydroxamic acids (5-CHA), showing medium size CHA as a new Zn-binding group. New reaction sequence was proposed for the synthesis of 5-membered alkylidene-cyclic-hydroxamic acids starting from butyrolactone. Compound 10c showed low mu M activity on HeLa cell extracts. From these results, cyclic hydroxamic acids will be further investigated to find more potent compounds.

  DOI：

  10.3109/14756366.2014.912214

文献信息

• 11,12-Cyclic thiocarbamate macrolide antibacterial agents
  申请人：Zhu Bin

  公开号：US20050250713A1

  公开（公告）日：2005-11-10

  The present invention is directed to novel macrolide antibacterial agents and processes for preparing them. The present invention is further directed to pharmaceutical compositions containing the novel macrolide antibacterial agents disclosed herein and their use in the treatment and prevention of bacterial infections.

  本发明涉及新型大环内酯抗菌剂及其制备方法。本发明还涉及含有本文所披露的新型大环内酯抗菌剂的药物组合物，以及它们在治疗和预防细菌感染中的应用。
• Microcapsules having activated release of core material therein
  申请人：Seitz E. Michael

  公开号：US20050277549A1

  公开（公告）日：2005-12-15

  The present invention is directed to microcapsules having polymeric shells that possess blocking groups (e.g., amine-blocking groups), the removal or cleavage of which act to initiate release of the core material therein, or increase the rate at which such core material is released. The present invention is further directed to the formulation of said microcapsules in aqueous dispersions, to the preparation of said microcapsules, and to the use of such microcapsules and dispersions thereof.

  本发明涉及具有聚合物壳的微胶囊，其具有阻塞基团（例如，胺阻塞基团），其去除或裂解作用于启动其中核心材料的释放，或增加这种核心材料释放的速率。本发明进一步涉及在水分散体系中制备这些微胶囊的配方，制备这些微胶囊的方法，以及这些微胶囊和其分散体系的用途。